Public Health - Maryland Pediatric Cancer Fund - Entities Eligible for Grants
HB0672 amends Maryland’s pediatric cancer fund law to narrow and clarify which entities may receive grants from the Maryland Pediatric Cancer Fund. The bill keeps the fund dedicated to pediatric cancer research and related administrative costs, but changes the grant language so that the remaining funds are directed to nonprofit hospitals, educational institutions, and other nonprofit organizations, rather than the broader prior categories that included eligible physicians, laboratories, and persons. It also preserves the existing requirement that grant money be used only for pediatric cancer research and not for institutional overhead or unrelated expenses.
The bill continues the structure of the fund as a special, nonreverting account administered by the Secretary of Health, supported by state appropriations and donations, with annual reporting to the General Assembly and regulations to implement the grant program. It maintains the cap that no more than 5% of the fund may be used for promotion and administration, including support for a childhood cancer organization and commission-related costs. The measure is framed as a public health bill and was enacted as Chapter 220, taking effect as an emergency measure upon enactment despite also containing a later effective date provision.
The bill’s impact on state law is limited but important: it revises Health-General § 20-120 to redefine eligible grant recipients and thereby channels pediatric cancer research funding toward nonprofit institutional recipients. This affects the Maryland Department of Health’s administration of the fund, the types of entities that can apply for grants, and the scope of allowable expenditures under the program. It does not change the fund’s purpose, funding source, or reporting obligations.
There is little visible controversy in the available record. No committee transcripts or recorded votes were provided, and the bill was ultimately approved by the Governor. The overall sentiment appears supportive and technical rather than contentious, with the legislation presented as a refinement of an existing pediatric cancer research program rather than a major policy shift. Any potential point of contention would likely center on the narrowing of eligible grantees, particularly the exclusion of individual physicians, laboratories, and non-entity recipients from direct grant eligibility.
HB0672 amends Maryland Health-General § 20-120 governing the Maryland Pediatric Cancer Fund. It narrows the categories of entities eligible to receive grants from the fund, limiting awards to nonprofit hospitals, educational institutions, and other nonprofit organizations, while removing prior references to eligible physicians, laboratories, and persons. The bill leaves intact the fund’s dedicated purpose, nonreversion rule, administrative cap, annual reporting requirement, and regulation-making authority, and it continues to require that grant funds be used only for pediatric cancer research and closely related administrative purposes.
The available record suggests broad support and little overt opposition. There are no committee transcripts or vote tallies indicating debate, and the bill was enacted and signed by the Governor. The measure appears to have been treated as a targeted administrative and programmatic adjustment to an existing pediatric cancer research fund rather than a controversial policy change.
The main substantive issue is the bill’s narrowing of grant eligibility. By replacing broader language that included eligible physicians, laboratories, and persons with a more limited set of nonprofit institutional recipients, the bill may have excluded some researchers or research-related entities from direct access to the fund. Any concern would likely come from stakeholders who preferred a wider pool of applicants or more flexible funding mechanisms, while supporters likely favored directing state dollars to established nonprofit institutions with research infrastructure.